Marinus Pharmaceuticals Income Statement

Financials in millions PKR. Fiscal year is October - September.

Millions PKR. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021	Sep '20 Sep 30, 2020
Revenue	13,951	10,989	10,984	6,898	6,064	6,425
Revenue Growth (YoY)	13.80%	0.05%	59.23%	13.76%	-5.62%	20.95%
Cost of Revenue	12,807	10,088	8,615	6,068	5,404	5,944
Gross Profit	1,144	900.67	2,369	830.38	659.27	480.96
Selling, General & Admin	604.24	487.88	394	328.19	307.54	266.29
Other Operating Expenses	-71.03	-29.36	72.7	-114.41	24.67	-23.46
Operating Expenses	533.21	458.51	466.71	213.78	332.21	242.83
Operating Income	611.16	442.16	1,902	616.6	327.07	238.13
Interest Expense	-624.66	-1,248	-624.67	-523.69	-262.13	-339.22
Interest & Investment Income	107.8	107.8	82.79	101.81	64.95	57.11
Earnings From Equity Investments	-178.25	-652.28	911.79	440.14	61.6	76.92
Currency Exchange Gain (Loss)	-	-	-	1.9	0.16	-2.44
Other Non Operating Income (Expenses)	-5.06	-5.06	-170.81	-47.12	-75.33	-29.64
EBT Excluding Unusual Items	-89.01	-1,355	2,101	589.65	116.31	0.85
Gain (Loss) on Sale of Investments	669.46	669.46	84.75	-199.27	-99.86	135.12
Gain (Loss) on Sale of Assets	10.62	10.62	94.35	3.13	10.14	26.39
Pretax Income	591.08	-675.33	2,280	393.51	26.59	162.36
Income Tax Expense	438.86	123.75	837.59	104.38	41.7	115.62
Net Income	152.22	-799.08	1,443	289.13	-15.11	46.74
Net Income to Common	152.22	-799.08	1,443	289.13	-15.11	46.74
Net Income Growth	-78.11%	-	399.05%	-	-	-88.41%
Shares Outstanding (Basic)	75	75	75	75	74	75
Shares Outstanding (Diluted)	75	75	75	75	74	75
Shares Change (YoY)	-0.10%	-	-	1.02%	-1.01%	-
EPS (Basic)	2.03	-10.66	19.26	3.86	-0.20	0.62
EPS (Diluted)	2.03	-10.66	19.26	3.86	-0.20	0.62
EPS Growth	-78.09%	-	399.05%	-	-	-88.41%
Free Cash Flow	3,285	-3,156	1,790	-553.32	-680.83	205.6
Free Cash Flow Per Share	43.87	-42.13	23.89	-7.38	-9.18	2.74
Dividend Per Share	2.500	1.000	7.500	0.606	0.980	0.777
Dividend Growth	-43.30%	-86.67%	1137.42%	-38.12%	26.01%	-54.17%
Gross Margin	8.20%	8.20%	21.57%	12.04%	10.87%	7.49%
Operating Margin	4.38%	4.02%	17.32%	8.94%	5.39%	3.71%
Profit Margin	1.09%	-7.27%	13.14%	4.19%	-0.25%	0.73%
Free Cash Flow Margin	23.55%	-28.72%	16.30%	-8.02%	-11.23%	3.20%
EBITDA	780.61	611.25	2,072	782.18	482.58	395.05
EBITDA Margin	5.59%	5.56%	18.87%	11.34%	7.96%	6.15%
D&A For EBITDA	169.45	169.09	169.9	165.58	155.52	156.92
EBIT	611.16	442.16	1,902	616.6	327.07	238.13
EBIT Margin	4.38%	4.02%	17.32%	8.94%	5.39%	3.71%
Effective Tax Rate	74.25%	-	36.73%	26.52%	156.83%	71.21%
Revenue as Reported	13,951	10,989	10,984	6,898	6,064	6,425
Advertising Expenses	-	0.18	0.76	1.24	0.11	0.13

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q